Clinical Trial Update: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating daily oral semaglutide tablets for individuals with overweight or obesity has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Rybelsus (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2026-02-25